Cite

HARVARD Citation

    Simpson, E. et al. (n.d.). 330 Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2 years. British journal of dermatology. p. . [Online]. 
  
Back to record